iTeos Therapeutics (NASDAQ:ITOS – Get Rating) had its price objective trimmed by JPMorgan Chase & Co. from $34.00 to $32.00 in a report published on Thursday, Benzinga reports. The firm currently has an overweight rating on the stock.
Separately, Wedbush decreased their price target on shares of iTeos Therapeutics from $45.00 to $33.00 and set an outperform rating on the stock in a research note on Thursday.
iTeos Therapeutics Stock Performance
ITOS stock opened at $14.12 on Thursday. The company’s 50-day simple moving average is $18.81 and its 200 day simple moving average is $19.40. iTeos Therapeutics has a 52 week low of $13.81 and a 52 week high of $37.26. The company has a market capitalization of $504.37 million, a PE ratio of 5.49 and a beta of 1.42.
Institutional Investors Weigh In On iTeos Therapeutics
About iTeos Therapeutics
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.